Researchers from Stony Brook University developed a new efficient graphene-based MRI contrast agent that's potentially safer and cheaper than current gadolinium-based agents. The new agent can also improve disease detection because of its sensitivity and diagnostic confidence.

Dr. Sitharaman, who led the research, has established a new company called Theragnostic Technologies which is set to commercialize this new agent.